AB-3028

N/A

Report date: 2025/12/17 20:02:10

Base Information

Drug NameAB-3028

Drug Alias NameAB-3028AB3028

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesArsenal Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesArsenal Biosciences Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A